Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403287 | 0.95 | TK1 (0.58) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13599906 | 0.92 | TK1 (0.54) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL24638622 | 0.91 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL14252429 | 0.91 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL20456356 | 0.91 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887784 | 0.90 | TK1 (0.56) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13403300 | 0.90 | TK1 (0.56) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887780 | 0.90 | TK1 (0.56) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL16772882 | 0.89 | TYMS (0.49) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL8739460 | 0.87 | TYMS (0.53) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067162-B2 | Replication; hybridization; kits | RIKEN (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100092971-A1 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID | RIKEN (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20080227104-A1 | Replication; hybridization; kits | RIKEN (JP) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092971-A1 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID | NME1, NGLY1, DNTT | TK1 21/4885CYP1A2 4856/4885CYP3A4 4806/4885 |
| US-20080227104-A1 | Replication; hybridization; kits | PCNA, POLL, RNGTT | TK1 300/4885CYP1A2 4851/4885CYP3A4 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.